Published by: MRG, Inc. and Fuji-Keizai
USA
Published: January 2003
No. of Pages: 160
Price: US $1,495.00
TABLE OF CONTENTS
1.0 Executive Overview
2.0 The Market Overview for Proteomics in Pharmaceutical
2.1. Definition of Proteomics Market
2.2. Recent Industry Trends That Impact Proteomics Market
3.0 Current Proteomics Market Participants by Market
3.1. Technologies Used in Proteomics
3.1.1. Emerging Proteomics Technologies
3.1.2. Proteomics Chip Providers
3.1.3. Proteomics Platform Providers
3.1.4. Reagent or Antibody Providers
3.1.5. Proteomics Informatics Tools and Database Providers
3.1.6. Proteomic Service Providers
3.1.7. Proteomics-based Drug Discovery Companies
3.2. The Drug Development Process
4.0 Drivers of Proteomics Market
4.1. Pharmaceutical Drug Discovery R&D
4.2. Japan to Plan Key Role in “Golden Age of Discovery”
4.3. Genomics Contribution to Drug Development
4.4. Need for Systems Approach to Biological Research
4.4.1. Limitations of DNA Chips and Expression Profiling
4.4.2. Technical Challenges with Protein Chips
4.4.3. Post Human Genome Project Era Proteomics Database
5.0 Case Studies in Proteomic Platforms for Pharmaceutical
R&D
5.1. Collaborative Landscape in Proteomics: Strategic Alliances
and Partnerships
5.2. Strategic Alliances in the Proteomics Market Segments
5.2.1. Alliances with Platform Providers
5.2.2. Alliances with Proteomics Arrays or Protein Chips
5.2.3. Alliances with Informatics and Database Providers
5.2.4. Alliances with Proteomic Reagent Providers
5.2.5. Alliances with Proteomic Service Providers
5.3. Recent Key Strategic Alliances and Partnerships
5.3.1. Applied Biosystems & HTS Biosystems: An R&D
and Marketing Collaboration
5.3.2. Bruker Daltonics & Roche: Platform Development
Collaboration
5.3.3. Celera & SomaLogic: Technology Access Collaboration
5.3.4. Ciphergen & Beckman Coulter: Robotic Upgrade
to Leading Platform
5.3.5. Correlogic & Ciphergen: Diagnostic Discovery
Collabroration
5.3.6. Gyros & Affibody: Technology Development Strategic
Alliance
5.3.7. MDS Proteomics & Thermo Finnigan: Platform Development
Collaboration
5.3.8. NeoGenesis & Mass General Hospital: Clinical
Collaboration
5.3.9. Phylos & Upstate: Reagent Development Collaboration
5.3.10. Large Scale Biology & NIEHS: Academic Research
Collaboration
5.3.11. Oxford GlycoSciences & BioInvent: Drug-Discovery
Collaboration
5.3.12. Proteome Systems & Itochu: An International
Joint Venture
6.0 Drug Discovery Pipeline Engaging Proteomics
7.0 Future Outlook for Proteomics
7.1. Forecast for Proteomics by Market Segments
7.1.1. Platform Provider Market Segment
7.1.2. Protein Chip Provider Segment
7.1.3. Informatics Provider Market Segment
7.1.4. Reagent Provider Market Segment
7.1.5. Services Provider Market Segment
7.1.6. Comparison of the Market Segment Forecasts
7.1.7. Proteomics Market Size by Segment, 2002~2006
7.2. Total Size of the Proteomics Market
8.0 Future Directions in Proteomics
8.1. Overview of Past Trends
8.2. Recent Developments in Genomics that Impact Proteomics
8.3. Indicators of Future Trends in Proteomics
9.0 Company Profiles
Each profile includes information about
• General description
of product/service,
• Employees,
• Technology application
& development,
• Public/private financial
status,
• Strategic alliances,
• Core strengths &
patents,
• Pharmaceutical partnerships,
and
• R&D implications
9.1. Protein Chip Providers
9.1.1. Aspira Biosystems
9.1.2. BioForce Nanosciences
9.1.3. Biosite Discovery
9.1.4. Glaucus Proteomics
9.1.5. Milagen, Inc.
9.1.6. Phylos
9.1.7. Protometrix
9.2. Platform Providers
9.2.1. 20/20 GeneSystems, Inc
9.2.2. Agilent Technologies
9.2.3. Applied Biosystems
9.2.4. Biacore AB
9.2.5. Ciphergen
9.2.6. CombiMatrix
9.2.7. HTS Biosystems
9.2.8. Kinexus
9.2.9. Large Scale Biology
9.2.10. Perkin-Elmer, Inc.
9.2.11. Prolinx
9.2.12. Proteome Systems Ltd.
9.2.13. Randox
9.2.14. SomaLogic
9.2.15. Zeptosens
9.2.16. Zyomyx, Inc.
9.3. Reagent Providers
9.3.1. Bioinvent
9.3.2. Cambridge Antibody Technology
9.3.3. LYNX
9.3.4. Upstate
9.4. Services Providers
9.4.1. GeneProt
9.4.2. Protagen AG
9.4.3. Syrrx
9.5. Informatics and Database Providers
9.5.1. AxCell Biosciences
9.5.2. Compugen
9.5.3. GeneFormatics
9.5.4. InforMax
9.5.5. Iconix Pharmaceuticals
9.5.6. LabVantage Solutions
9.5.7. Matrix Science
9.5.8. Nonlinear Dynamics
9.5.9. ProteoMetrics
9.6. Future Directions in Proteomics
9.6.1. ACE BioSciences
9.6.2. Archemix
9.6.3. Beyond Genomics
9.6.4. Celera Genomics
9.6.5. MDS Proteomics, Inc.
9.6.6. NeoGenesis Pharmaceuticals, Inc.
9.6.7. Oxford GlycoSciences
10.0 Lessons Learned and Emerging Opportunities
10.1. Genomics Companies Restructure and Focus on Proteomics
10.2. Challenges of Drug Discovery R&D Process
10.3. Next Hot Development Areas in Proteomics
10.4. Proteomics Opportunities
10.5. Role in Drug Discovery
10.5.1. Role in Toxicology and Toxicogenomics
10.5.2. Role in Basic Research
10.6. Large-Scale Proteomics Takes Off
11.0 Summary
APPENDIX A – Listing of Proteomics Vendors
APPENDIX B – Proteomics Glossary
Press Release
Order
